In another study, an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) peptide vaccine using KLH as the carrier protein was shown to produce long-lasting anti-PCSK9 antibodies and is considered to be the primary vaccine for the treatment of dyslipidemia in the future (Kawakami et al., 2018). This evidence concerns the gene PCSK9 and metabolic syndrome.